Enhanced Group Inc. 8-K

What Happened Enhanced Group Inc. (ENHA) filed an 8-K on June 15, 2026 disclosing a securities purchase agreement for a private placement of 12,853,468 shares of Class A common stock and accompanying warrants to purchase 12,853,468 shares. The combined price per share and warrant is $3.89 (NYSE close on June 12, 2026), producing expected gross proceeds of approximately $50.0 million. Investors include Apeiron Investment Group Limited (the Company’s controlling shareholder, whose sole voting equityholder is Christian Angermayer) and CEO/Director Maximilian Martin. The offering is expected to close in three tranches (≈$25.0M first closing on/about June 17, 2026; ≈$11.75M on/about June 22, 2026; ≈$13.25M after stockholder consent). The Company intends to use part of the first-closing proceeds to repay in full a March 18, 2026 working capital promissory note to Apeiron and the balance for working capital and growth of its telehealth and consumer health platform.

Key Details

• 12,853,468 Shares and 12,853,468 Warrants; combined price $3.89 per Share+Warrant; gross proceeds ≈ $50.0M (excludes future cash exercise of warrants).
• Tranches: ~ $25.0M First Closing (expected ~June 17, 2026), ~$11.75M (~June 22, 2026), ~$13.25M after stockholder consent and information statement distribution.
• Note repayment: portion of First Closing proceeds to repay and terminate Apeiron Working Capital Promissory Note (dated March 18, 2026); termination effective after first full business day following First Closing.
• Warrant terms: exercisable at issue, 5-year term, $3.89 exercise price, accelerated expiration if stock ≥ $20.00 for 20 consecutive trading days; 24‑month anti‑dilution protections for bona fide capital raises; ownership exercise cap default 4.99% (holder may elect up to 19.99%).
• Registration Rights: Company agreed to file a registration statement covering the Shares and Warrant Shares within 30 days of each closing and use commercially reasonable efforts to have it declared effective promptly.
• Governance/approval: Controlling stockholder intends to deliver a Written Consent (around June 15, 2026) approving issuance terms, including issuance that may exceed 19.99% and related‑party/CEO issuances; Company to file and distribute an information statement as required.

Why It Matters This is a material dilutive financing: the private placement plus exercisable warrants could increase shares outstanding and provide up to ~$50M in immediate capital. Part of the proceeds will eliminate a related-party short‑term promissory note to Apeiron, reducing that debt burden. Warrants exercisable immediately and registration rights mean holders can potentially convert and resell shares, creating future dilution if exercised. The controlling shareholder’s participation and the planned written consent to waive certain NYSE approval limits are important governance points investors should note. The Company has committed to registering the securities, which will enable resale once the registration statement is effective.